Anagrelide en es it fr

Anagrelide Brand names, Anagrelide Analogs

Anagrelide Brand Names Mixture

  • No information avaliable

Anagrelide Chemical_Formula


Anagrelide RX_link

Anagrelide fda sheet

Anagrelide FDA

Anagrelide msds (material safety sheet)

Anagrelide MSDS

Anagrelide Synthesis Reference

No information avaliable

Anagrelide Molecular Weight

256.088 g/mol

Anagrelide Melting Point

280 oC

Anagrelide H2O Solubility

Very slightly soluble

Anagrelide State


Anagrelide LogP


Anagrelide Dosage Forms

Capsules (0.5 mg or 1 mg)

Anagrelide Indication

For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

Anagrelide Pharmacology

Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 = 36nM) inhibitor of phosphodiesterase-III.

Anagrelide Absorption

No information avaliable

Anagrelide side effects and Toxicity

There are no reports of overdosage with anagrelide, however thrombocytopenia, which can potentially cause bleeding, is expected from overdosage. Single oral doses of anagrelide at 2,500, 1,500 and 200 mg/kg in mice, rats and monkeys, respectively, were not lethal. Symptoms of acute toxicity were: decreased motor activity in mice and rats and softened stools and decreased appetite in monkeys.

Anagrelide Patient Information

Anagrelide Organisms Affected

Humans and other mammals